Sort Through Options for Managing Heart Failure

December 2025

You’ll hear buzz about finerenone (Kerendia) and the GLP-1 receptor agonists semaglutide and tirzepatide for certain types of heart failure.

There’s some evidence for these in heart failure with mildly reduced ejection fraction (HFmrEF) or preserved EF (HFpEF)...with an EF greater than 40% or 50%, respectively.

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) previously used for CKD...now approved for HF with EF ≥40%.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote